- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: Julie Kennerly-Shah, PharmD, on How Biosimilars Can Help Curb COVID-19's Impact
We sat down with Julie Kennerly-Shah, PharmD, assistant director of Pharmacy at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute to discuss cost cutting with biosimilars.
As summer fades away and the United States prepares for a potential second wave of coronavirus disease 2019 (COVID-19) cases, many are worried that economic impacts and rising health care costs will continue unless action is taken. Europe’s competitive biosimilar market has proven that biosimilars have the potential to lower costs. But with existing barriers, such as lack of education and payer oversight of formularies, and the continuing pandemic, there is some debate on whether biosimilars will have the same impact in the United States.
We sat down with Julie Kennerly-Shah, PharmD, assistant director of Pharmacy at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute to discuss how biosimilars can help curb costs in the time of COVID-19 and beyond.
To learn more about COVID-19's impact on biosimilars, click here.
To learn more about biosimilar education, click here.
To learn more about step therapy, click here.
To learn more about payer interference on preferred drugs, click here.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
